Body Dysmorphic Disorders

The Establishment of the Facility Demonstrates the Company's Commitment to Delivering Differentiated Solutions to Gynecology and Pediatrics Challenges SHANGHAI, Dec. 22, 2023 /PRNewswire/ -- Changchun GeneScience Pharmaceutical ("GenSci"), a subsidiary of Changchun High-Tech Industries (Group), held a groundbreaking ceremony for its new global headquarters and research & development (R&D) center at Shanghai Zhangjiang International Medical Park on December 15th. With an increasing focus on women`s and children`s health, the Chinese government has been intensifying efforts to improve healthcare services for these demographics, embedding their care within the wider framework of the country's economic and social development policies. The establishment of the R&D center sets the stage for GenSci to further advance the convergence of industry, academia, research and the medical community. By leveraging cutting-edge R&D capabilities and the application of artificial intelligence technologies, GenSci is well-positioned to provide premium health solutions for women and children. The initiative aligns with GenSci's commitment to harnessing science and technology to protect and enhance the health of these vulnerable groups. Continue Reading Changchun GeneScience Pharmaceutical Co., Ltd. The construction of this facility is progressing as planned, and it is expected to be fully operational by 2027, providing a capacity to accommodate up to 2,000 R&D professionals. Supporting the Healthy China Initiative: Focusing on the Health Needs of Women and Children Recognizing the pivotal role of women and children's health in the nation's overall well-being, the government has designated this field as a critical priority. This is evident in the implementation of significant strategic initiatives such as the Healthy China Initiative (2019-2030), the Outline for Children's Development in China (2021-2030), and the Outline for Women's Development in China (2021-2030). These key documents underscore our unwavering commitment to enhancing nationwide awareness regarding the specific needs of women and children, with an overarching objective of safeguarding their health. The health of women and children confronted with new challenges. While the incidence of common childhood diseases has decreased, there is a rise in lifestyle-related health issues in children, including early puberty, myopia, growth deficiencies, body image concerns, immune system abnormalities, and mental health disorders. In addition, women are generally grappling with reproductive health issues and the effects of menopause that can significantly impact their quality of life. Moreover, the periods of pregnancy and early childhood present vital opportunities to avert diseases that can develop later in life. Enhanced health management for women and children during these key stages can help prevent long-term health issues, carrying significant implications for the broader society. Providing Premier Global Maternal and Child Health Solutions through Distinctive Innovation Aligned with national healthcare directives, GenSci has ramped up its R&D investments to address the unmet health needs of women and children. The company has already developed the capability to innovate across various product categories, including biopharmaceuticals, chemical drugs, live bacterial preparations (LBPs) and medical devices. The GenSci general manager, Dr. Jin, pointed out that their product innovations are designed to deliver substantial unique benefits. The establishment of the Zhangjiang R&D center is a testament to GenSci's commitment to independent innovation. Since its founding in 1997, GenSci has introduced several groundbreaking therapies, including the GenSci Recombinant Human Growth Hormone, GenSci Heng Recombinant Human Follicle-Stimulating Hormone and Jinfuning Recombinant Human Granulocyte-Stimulating Factor Gel. The company's proprietary innovations and outstanding contribution in the field of child growth and development were recognized when its "Development and Industrialization of Recombinant Human Growth Hormone Series Products" project won the Second Prize of the 2015 National Science and Technology Progress Award. The accolade underscores GenSci's expertise in independent innovation within China's pharmaceutical sector. With an ongoing focus on growth disorders in children, GenSci has expanded its attention to the broader spectrum of children's health. This includes addressing concerns such as abnormal sexual development, obesity, respiratory and digestive health, allergies and autoimmune disorders, neurological and speech development, as well as concerns related to body image. As an illustration, GenSci has been develop an industry-leading ultra-long-acting growth hormone that is administered monthly since 2020, as well as innovative oral treatments for short stature. The company has also been creating comprehensive range of solutions designed to diagnose and treat precocious puberty, including rapid sex hormone tests and long-acting gonadotropin-releasing hormone analogs for treating central precocious puberty. Furthermore, GenSci has been adopting a comprehensive approach that addresses women's health needs throughout their life cycle. This initiative includes support for assisted reproduction, menopausal health, and the treatment of prevalent gynecological conditions. Significantly, the company has been developing the world's first lytic enzyme and live bacterial preparation (LBP) for treating vaginitis caused by drug-resistant bacteria, offering an alternative to antibiotics and addressing the issue of drug resistance. "GenSci has built a globally innovative and competitive R&D product pipeline," Dr. Jin declared. "By 2025, the firm will boast an extensive portfolio, with the expectation of launching more than four top-tier innovative drugs and five novel medical devices annually in the years to come." Enhancing Collaboration Across Industry, Academia, Research, and Healthcare Providers to Tackle Key Issues in Women's and Children's Health GenSci, through a combination of proprietary R&D and collaborative efforts with partners, has developed a suite of sophisticated R&D technology platforms that drive forward-thinking product development. The platforms focus on the protein drug sustained-release technology, mucosal delivery systems for nucleic acid medications, antibody-drug conjugate (ADC) technology, and innovations in ultrasound and hydrogel technologies. Integrating AI technology, GenSci covers the entire drug innovation process, from initial design and screening to process development and formulation. Moreover, the company promotes the introduction and adoption of cutting-edge concepts and technologies by facilitating synergistic integration of industry, academia, research and the medical community, ensuring effective cooperation among these stakeholders. GenSci has formed enduring and robust partnerships with nearly 20 prominent universities, including Shanghai Jiao Tong University and Zhejiang University. The company has also engaged in various scientific research collaborations with institutions such as Shanghai Jiao Tong University, Shandong University, and the Center for Excellence in Brain Science and Intelligence Technology at the Chinese Academy of Sciences. Additionally, GenSci has joined forces with numerous maternity and pediatric departments within both general and specialized hospitals through multicenter clinical trials and joint applications for national projects. As part of these alliances, the company contributes its substantial technical expertise and digital platform capabilities — skills acquired during product development — to these hospitals at no cost. Frontline doctors are engaged to review and provide feedback on these tools, aiding the ongoing enhancement of GenSci's research and digital capabilities in gynecology and pediatrics. Additionally, GenSci has established collaborations with numerous hospitals in the development of digital medical assistance systems，it actively engages in medical research to achieve technological breakthroughs and plays a pivotal role as a high-tech innovation platform in specialized treatment fields. Through deep cooperation and extensive coverage, it truly realizes co-creation and win-win outcomes in medical research. The groundbreaking of GenSci's global innovation hub and R&D center enpowers the company to fully utilize its expertise in gynecology and pediatrics. GenSci intends to introduce innovative therapies for oncology, immunology, hearing loss, and drug-resistant bacterial infections, aiming to address unmet clinical needs. With its advanced strategic positioning, substantial investment in R&D, and unwavering commitment to product innovation, GenSci continues to strive towards tackling significant medical challenges while providing exceptional exceptional treatment options for healthcare professionals and patients. SOURCE Changchun GeneScience Pharmaceutical Co., Ltd.

DUBLIN--( BUSINESS WIRE )--The "Neurostimulation: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive study of the global market for neurostimulation technologies and devices. It provides a detailed description of the different types of neurostimulation technologies and devices (invasive and noninvasive) and their current and historical market revenues. The human nervous system works as the chief commander of the human body. The medical science community has long believed that it has huge potential in treatment of human body disorders. Neurostimulation technology involves the alteration or modulation of nerves. Neurostimulation devices deliver electrical current or magnetic impulses directly to nerves in order to modify their activity. Over the past 25 to 30 years, neurostimulation has emerged as one of the most dynamic fields of therapy, and has been actively investigated for treatment of a range of clinical conditions including chronic pain, movement disorders (Parkinson's disease, tremor, dystonia and others), epilepsy, psychiatric disorders, functional restoration, cardiovascular disorders, gastrointestinal disorders and genitourinary disorders. It is also said to consist of "drug-free solutions." Currently, the potential of neurostimulation technology is actively being explored for other clinical conditions including obesity, tinnitus and central nerve system disorders. Given the vast size of the potential treatment population and the many ongoing scientific discoveries and technological advances in neurostimulation technologies, the market for neurostimulation devices market is poised for significant growth. Other factors expected to aid in the market boom include many countries' growing elderly populations and increasing trends toward the use of nondrug therapies, greater expectations for quality of life, and improved patient attitudes toward receiving medical attention. Neurostimulation technologies represent a cutting-edge field in neuroscience and medical science, aiming to modulate the activity of the nervous system to treat a wide range of neurological and neuropsychiatric disorders. These innovative techniques involve the application of electrical, magnetic or optogenetic stimuli to specific areas of the brain or nervous system, offering the potential to alleviate symptoms, restore lost function and enhance cognitive capabilities. Neurostimulation is based on the concept of neuromodulation, where electrical signals are applied to neurons to alter their activity and influence neural networks. Neurons communicate through electrical impulses, and by selectively stimulating or inhibiting specific neural populations, neuroscientists and clinicians can modulate brain function. This report also covers in detail the therapeutic applications of neurostimulation technologies and devices, including chronic pain, Parkinson's disease, epilepsy, urinary and fecal incontinence, obstructive sleep apnea, essential tremor, obsessive compulsive disorder, major depressive disorder/clinical depression and others. An in-depth analysis of the global market for neurostimulation technologies and devices includes historical data and market projections by device type, therapeutic application and region. Report Includes Estimation of the market size and analyses of market trends, with data from 2020 to 2022, estimates for 2023 and projection of CAGR through 2028 Description of Dorsal Root Ganglion (DRG) neurostimulator system and discussion on approved indications of stimulation therapy for various diseases Detailed description of various types of stimulation such as spinal cord stimulation, transcutaneous electrical nerve stimulation, deep brain stimulation, sacral nerve stimulation, Vagus nerve stimulation, hypoglossal nerve stimulation, and transcranial magnetic stimulation; and discussion on their mode of action and advantages Information on recent therapy improvements and new indications for use, and discussion on alternatives to traditional stimulation therapies Coverage of ongoing scientific discoveries and technological advances in neurostimulation technologies and insights into marketed and pipeline (R&D) products, product recalls and reimbursement policies Market share analysis of neurostimulation devices by application, type and region, and evaluation of market size and forecast, and detailed analysis of drivers, challenges and opportunities affecting market growth Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies Comprehensive company profiles of major players Axonics Inc Boston Scientific Corp Medtronic PLC Synapse Biomedical Inc Xavant Technology Key Attributes: Report Attribute Details No. of Pages 160 Forecast Period 2023 - 2028 Estimated Market Value (USD) in 2023 $8.2 Billion Forecasted Market Value (USD) by 2028 $11.7 Billion Compound Annual Growth Rate 7.4% Regions Covered Global Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market and Technology Background Overview of Neurostimulation Types of Neurostimulation Technologies Spinal Cord Stimulation Deep Brain Stimulation Sacral Nerve Stimulation (Sns) Vagus Nerve Stimulation Hypoglossal Nerve Stimulation Transcutaneous Electrical Nerve Stimulation Transcranial Magnetic Stimulation (Tms) Other Neurostimulation Technologies Therapeutic Applications for Neurostimulation Chronic Pain Management Neurological Disorders Urinary and Fecal Incontinence Obstructive Sleep Apnea Chronic Migraine and Headache Cardiovascular Diseases Gastrointestinal Disorders Obesity Psychiatric Disorders Technological Developments Mri Compatibility Rechargeable and Non-Rechargeable Devices Chapter 4 Market Dynamics Market Trends Drivers Market Restraints Chapter 5 Market Breakdown by Technology/Device Type Global Market for Neurostimulation Devices by Type Spinal Cord Stimulation (Scs) Devices Transcutaneous Electrical Nerve Stimulation (Tens) Devices Deep Brain Stimulation (Dbs) Devices Sacral Nerve Stimulation (Sns) Devices Vagus Nerve Stimulation (Vns) Devices Hypoglossal Nerve Stimulation (Hgns) Devices Market Size and Forecast Transcranial Magnetic Stimulation (Tms) Devices Other Types of Neurostimulation Devices Chapter 6 Market Breakdown by Therapeutic Application Global Market for Neurostimulation Devices by Therapeutic Application Chronic Pain Urinary and Fecal Incontinence Parkinson's Disease Epilepsy Obstructive Sleep Apnea (Osa) Essential Tremor Major Depressive Disorder (Mdd)/Clinical Depression Obsessive Compulsive Disorder (Ocd) Other Therapeutic Applications Chapter 7 Market Breakdown by Region Global Market for Neurostimulation Devices by Region North America Europe Asia-Pacific Rest of the World Chapter 8 Regulatory Structure Regulatory Framework U.S. European Union Japan Chapter 9 Key Products and Technologies on the Market Recent Therapeutic Improvements and New Indications Spinal Cord Stimulation Deep Brain Stimulation Sacral Nerve Stimulation (Sns) Axonics Medtronic Vagus Nerve Stimulation Hypoglossal Nerve Stimulation Transcutaneous Electrical Nerve Stimulation Transcranial Magnetic Stimulation Other Types of Stimulation New Indications and Neurostimulation Therapies Chapter 10 Emerging Technologies and Developments Emerging Technologies and Developments Closed-Loop Neurostimulation Non-Invasive Brain Stimulation Techniques High-Frequency Stimulation Magnetic Resonance-Guided Focused Ultrasound Optogenetics Bioelectronic Medicine Wireless and Remote-Controlled Devices Chapter 11 Recent M&A M&A in the Neurostimulation Technologies Industry Chapter 12 Competitive Landscape Company Market Shares by Product Segment Spinal Cord Stimulation Devices Deep Brain Stimulation Devices Sacral Nerve Stimulation Devices Vagus Nerve Stimulation Devices Hypoglossal Nerve Stimulation Devices Transcranial Magnetic Stimulation Devices Transcutaneous Electrical Nerve Stimulation Devices Recent Industry Activities Chapter 13 Company Profiles Abbott Laboratories Aleva Neurotherapeutics Sa Avery Biomedical Devices Inc. Axonics Inc. Bioinduction Ltd. Bioventus LLC Biowave Corp. Boston Scientific Corp. Brainsway Ltd. Cochlear Americas Cvrx Inc. Electrocore Inc. Inspire Medical Systems Inc. Integer Holdings Corp. Laborie Inc. Livanova plc Mag & More GmbH Magstim Inc. Medtronic plc Nalu Medical Inc. Neuromed Consulting Inc. Neurometrix Inc. Neuronetics Inc. Neuropace Inc. Neurosigma Inc. Neurovalens Ltd. Nevro Corp. Nexstim plc Nyxoah Sa Soterix Medical Inc. Synapse Biomedical Inc. Xavant Technology (Pty) Ltd. Zoll Medical Corp. For more information about this report visit https://www.researchandmarkets.com/r/7hblrg About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

THURSDAY, July 27, 2023 (American Heart Association News) -- Late one evening, Dawn Berry took a call from her grandmother's nursing home. Her grandmother had been found unresponsive in bed. What should they do? Dawn, who was then 43, had worked in the medical field for more than 20 years in her hometown of Oklahoma City. When her grandmother had a severe stroke at home a few months earlier, Dawn's aunts and uncles authorized her to make medical decisions. Now she made another: Send Grandma to the emergency room. Dawn arrived around 9 p.m. Awake most of the night coordinating care, she was talking to a doctor about her grandmother – who was having complications from the stroke – when Dawn felt the room start spinning. By now it was around 5 a.m. She blamed the episode on stress. After going home to rest, she returned to her grandmother's bedside. She felt a little off balance, but again dismissed it as stress and exhaustion. Later that week, Dawn still felt unsteady. At one point, she tilted to the right and began falling. She might've hit the ground had her cousins not been there to catch her. The next morning, she started cooking French toast for her daughter, Izzy Berry-Northcutt, and her sister, Dana Berry. The three live together. The right side of Dawn's face felt odd. She touched it and couldn't feel anything. She dug her nails into her neck. Still nothing. "Dana, I think I had a stroke," she said. At the hospital, bloodwork and a CT scan showed no problems. Still, she was admitted for observation and further testing. The next day – Jan. 12, 2020 – an MRI showed she'd had a stroke. Two, actually; the other occurred at some unknown point in the past. Doctors couldn't pinpoint the cause. They blamed it on stress and her weight. At the time, Dawn weighed 465 pounds. She had never been thin. By her senior year of high school, she carried 180 pounds on her 5-foot-7 frame. "In the Black community, bigger is better," she said. "It's instilled in us. The bigger the woman is, the better she can sing. The better she can cook. It's a thing that's hard to resist." When she was 26, Dawn gave birth to Izzy and raised her as a single mom. That started her path of eating for comfort. Her habit worsened when her mother, who had heart disease, diabetes and high blood pressure, died at 56. Her father had some similar issues and died when he was 57. Although Dawn was never diagnosed with diabetes, she was on two blood pressure medications by the time she was 40. Meanwhile, her job was stressful. She'd worked in ER scheduling and bed assignments and had assisted hospital case managers and social workers. And even though the smallest amount of walking wore her out, Dawn felt the need to hide it all. What little energy remained she put into looking "put together and stylish." Following the stroke, Dawn felt like everything had caught up to her. She also endured another blow: Grandma died while Dawn was still in the hospital. She missed the funeral. The stroke left Dawn with few deficits – and new priorities. She didn't want her daughter to be without a mother. By the time Dawn got home from the hospital, Dana had filled their refrigerator and cupboards with healthy food. Dawn also started seeing a therapist. In June 2020, Dawn began the process of preparing to undergo bariatric surgery for weight loss. Before, she'd dismissed it as cheating. Now she saw how much education and discipline it involved. Before the surgery, on Dec. 15, 2020, she'd lost 65 pounds. Since then, she's lost an additional 140 pounds and counting. She takes only one blood pressure medication. "It's been hard to retrain my brain to eat smaller portions," she said. "This is definitely not the easy way out." Dawn walks up to 4 miles a day. She also organizes a team, called "Rhythm and Shoes," to walk the American Heart Association's Oklahoma City Heart & Stroke Walk every year. "There's a freedom in walking that I haven't felt since high school," said Dawn, who is now a cardiac device coordinator at a heart hospital. "It's wonderful." This past spring, she went to Hawaii with Dana and Izzy. It was her first time on a plane in 20 years and her first trip ever to the beach. "My life is just a lot of living it up again," she said. Despite her achievements, Dawn still fights body dysmorphia. "I don't see myself the way others see me," she said. "I can look in a mirror and see old Dawn." One person who only sees a new Dawn is her close friend Lindsay Gruntmeir. "I'm impressed by how strong and tenacious she's been because I know it's been hard," Gruntmeir said. Before Dawn's weight loss, the two would rarely go out to eat and would never go to a concert, she said. "Now we're doing all these things," she said. "She's always come across as super confident, but in some ways it was defensive. Now it's like a quieter confidence." American Heart Association News covers heart and brain health. Not all views expressed in this story reflect the official position of the American Heart Association. Copyright is owned or held by the American Heart Association, Inc., and all rights are reserved. By Diane Daniel, American Heart Association News Posted July 2023